Lenvatinib + Lenvatinib + Dacarbazine
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IV Melanoma
Conditions
Stage IV Melanoma
Trial Timeline
Apr 1, 2010 → Nov 1, 2014
NCT ID
NCT01133977About Lenvatinib + Lenvatinib + Dacarbazine
Lenvatinib + Lenvatinib + Dacarbazine is a phase 1/2 stage product being developed by Eisai for Stage IV Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01133977. Target conditions include Stage IV Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01133977 | Phase 1/2 | Completed |
Competing Products
20 competing products in Stage IV Melanoma